Falchook, Gerald S.
Reeves, James
Gandhi, Sunil
Spigel, David R.
Arrowsmith, Edward
George, Daniel J.
Karlix, Janet
Pouliot, Gayle
Hattersley, Maureen M.
Gangl, Eric T.
James, Gareth D.
Thompson, Jeff
Russell, Deanna L.
Patel, Bhavickumar
Kumar, Rakesh
Lim, Emerson
Article History
Received: 22 September 2023
Accepted: 22 January 2024
First Online: 2 March 2024
Declarations
:
: Gerald S. Falchook: Royalties (self): Wolters Kluwer (2014-present); Advisory role (to institution): Fujifilm (2018), Silicon (2020, 2021), Navire (2021), Turning Point (2021), Predicine (2021), Inspirna (2021), Regeneron (2021) Advisory role (self): EMD Serono (2010, 2011); Speakers honorarium for CME: Total Health Conferencing (2019), Rocky Mountain Oncology Society (2020); Travel (self, for work or research related to institution): Bristol Myers Squibb (2015), EMD Serono (2011, 2012, 2013), Fujifilm (2018), Millennium (2013), Sarah Cannon Research Institute Research funding [to institution, for any trial for which I have been the PI (ever) or subinvestigator (minimum last 4 years): 3-V Biosciences, Abbisko, AbbVie, ABL Bio ADC Therapeutics, Accutar, Aileron, American Society of Clinical Oncology, Amgen, ARMO/Eli Lilly, Artios, AstraZeneca, BeiGene, Bioatla, Bioinvent, Biothera, Bicycle, Boehringer Ingelheim, Celldex, Celgene, Ciclomed, Curegenix, Curis, Cyteir, Daiichi, DelMar, eFFECTOR, Eli Lilly, EMD Serono, Epizyme, Erasca, Exelixis, Freenome, Fujifilm, Genmab, GlaxoSmithKline, Hutchison MediPharma, IGM Biosciences, Ignyta, ImmunoGen/MacroGenics, Incyte, Jacobio, Jounce, Kolltan, Loxo/Bayer, MedImmune, Millennium, Merck, miRNA Therapeutics, Molecular Templates, National Institutes of Health, Navire, NiKang, Novartis, OncoMed, Oncorus, Oncothyreon, Poseida, Precision Oncology, Prelude, PureTech, Pyramid, RasCal, Regeneron, Relay, Rgenix, Ribon, Samumed, Sapience, Silicon, Simcha, Sirnaomics, Strategia, Syndax, Synthorx/Sanofi, Taiho, Takeda, Tarveda, Teneobio, Tesaro, Tocagen, Turning Point, U.T. MD Anderson Cancer Center, Vegenics, Xencor. James Reeves: None. Sunil Gandhi: None. David Spigel: None. Edward Arrowsmith: Tennessee Oncology Stock. Other Ownership Interests: One Oncology Research Funding: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Calistoga Pharmaceuticals, Celgene, Cephalon, Chorus, Cougar Biotechnology, Eisai, EMD Serono, Evelo Biosciences, Exelixis, Genentech, Gilead Sciences, Incyte, Merck Sharp & Dohme, Millennium, Modra Pharmaceuticals, Novartis, Oncogenex, Onyx, Peloton Therapeutics, Pfizer, Sarah Cannon Research Institute, Takeda, Clovis Oncology, Lilly, Infinity Pharmaceuticals, Janssen Research & Development Travel, Accommodations, Expenses: Flatiron Health, OneOncology, Sarah Cannon Research Institute. Other Relationship: Sarah Cannon Research Institute. Daniel J. George: Consultant for Astellas, AstraZeneca, Bayer H/C Pharmaceuticals, BMS, Constellation Pharmaceuticals, Exelixis, Inc, Flatiron, IdeoOncology (formerly Nexus), Janssen Pharmaceuticals, Merck Sharp & Dohme, Michael J Hennessey Associates, Myovant Sciences, Inc, Physician Education Resource LLC, Pfizer, PlatformQ, Propella TX–Consultant (formerly Vizuri), RevHealth, LLC, Sanofi, Seattle Genetics, WebMD, and Xcures. Speaker’s honorarium for Bayer H/C Pharmaceuticals, EMD Serono, Exelixis, Inc, Ipsen, Michael J Hennessey Associates, Pfizer, Sanofi, UroGPO, and UroToday. Advisory Role (self and institution) for Astellas, AstraZeneca, Capio Biosciences, and Modra Pharmaceuticals B.V. Travel accommodations from Bayer H/C Pharmaceuticals, Exelixis, Inc, Sanofi, and UroToday. Research funding (self and institution) from AstraZeneca, Astellas, BMS, Calithera (institution only), Exelixis, Inc, Janssen Pharmaceuticals, Novartis (institution only), Pfizer, and Sanofi. Steering Committee for Astrazeneca, Bayer H/C Pharmaceuticals, BMS, Leidos Biomedical Research Inc, Nektar Therapeutics, and Pfizer. Sr Editor for American Association for Cancer Research and Co‐Editor‐in‐Chief for Millennium Medical Publishing, Clinical Advances in Hematology & Oncology. Independent contractor for Axess Oncology. Independent Data Monitoring Committee for Janssen Pharmaceuticals. Janet Karlix: None. Gayle Pouliot: Employee of AstraZeneca and may own stock or stock options. Maureen M. Hattersley: Employee of AstraZeneca and may own stock or stock options. Eric T Gangl: Employee of AstraZeneca and may own stock or stock options. Gareth D James: Contractor for AstraZeneca. Jeff Thompson: Employee of AstraZeneca and may own stock or stock options. Deanna Russell: Employee of AstraZeneca and may own stock or stock options. Bhavickumar Patel: Employee of AstraZeneca and may own stock or stock options. Rakesh Kumar: Employee of AstraZeneca and may own stock or stock options. Emerson Lim: None.
: The study was conducted in accordance with the protocol and consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, applicable ICH Good Clinical Practice guidelines, and applicable laws and regulations (Independent Ethics Committee/Institutional Review Board).
: Written informed consent was obtained from all patients prior to enrollment into the study.
: Not applicable; no personal or identifying data for patients have been included in this article.